Backed by NEA and Norwest.
About the role
You will be expected to travel periodically based on the needs of the business, including attendance at Together Weeks, Together Days, and functional meetings as requested by the team. Employees are expected to work on hybrid schedules, consistent with local office practices and the terms of the companies in office policy as in effect from time to time.
What they're looking for
- Identify, assess, and escalate legal and business risks in proposed agreements, and provide practical, business-oriented recommendations to internal stakeholders and senior leadership
- Support diligence and contract review in connection with corporate transactions, financings, licensing deals, and potential partnerships or M&A activity
- Maintain and continuously improve the company's contract management system, templates, and standard terms to ensure consistency, compliance, and efficiency
- Provide training and guidance to internal stakeholders on contracting policies, procedures, and risk considerations
- Manage and coordinate with outside counsel on specialized or high-complexity matters as needed
- J.D. from an accredited law school and active membership in good standing with at least one U.S. state bar
More about this role
Working with Us
MBX Biosciences is a clinical-stage biopharmaceutical company headquartered in Carmel, Indiana, with a secondary office in Burlington, MA. Our mission is to transform the lives of people impacted by endocrine and metabolic disorders through our novel precision peptides.
Leveraging our proprietary Precision Endocrine Peptides (PEPs)™ platform, we are pioneering technology designed to overcome key limitations of existing therapies and enhance efficacy, tolerability, safety and convenience. Our team is advancing a pipeline of novel candidates with clinically validated targets, established endpoints for regulatory approval, and strong market potential.
Our pipeline includes canvuparatide (MBX 2109) for the treatment of chronic hypoparathyroidism, currently preparing for Phase 3 development, and a growing obesity portfolio that includes MBX 4291 in Phase 1 development, MBX 5765, a next-generation amycretin prodrug designed for once-monthly-dosing, as well as MBX 6180, a GLP/GIP/GCGR triple agonist prodrug for once monthly dosing; all of which optimize our PEP platform.
If you’re passionate about advancing innovative treatments for patients and shaping the future of...
Browse similar: Startup jobs